In my last post there was an interesting items on Bifidobacteria that I want to dig into:
“Bifidobacteria are common and frequently dominant members of the gut microbiota of many animals, including mammals and insects. Carbohydrates are considered key carbon sources for the gut microbiota, imposing strong selective pressure on the complex microbial consortium of the gut. Despite its importance, the genetic traits that facilitate carbohydrate utilization by gut microbiota members are still poorly characterized. Here, genome analyses of 47 representative Bifidobacterium (sub)species revealed the genes predicted to be required for the degradation and internalization of a wide range of carbohydrates, outnumbering those found in many other gut microbiota members.” 
Crohn’s Disease[CD] have problems with starches/carbohydrates, and we find:
“Lactobacillus and Bifidobacteria decreased obviously but Bacteroid increased in CD patients” 
“except for a decrease in bifidobacteria in the active state of IBD,”
“among the few bacterial groups considered, only bifidobacteria were significantly decreased in IBS samples.” 
“Rifaximin, a rifamycin derivative, has been reported to induce clinical remission of active Crohn’s disease (CD)…it caused an increase in concentration of Bifidobacterium, Atopobium and Faecalibacterium prausnitzii.” 
“with lower levels of bifidobacteria, celiac patients have an imbalance in the intestinal microbiota” 
“In comparison to patients with fibromyalgia, the RA patients had significantly less bifidobacteria” – NOTE: there was no comparison to controls in this study.
Treatment Results – Suggestions
“We found a significant rise in both Lactobacillus and Bifidobacteria in those taking the Lactobacillus casei strain Shirota(Yakult) , and there was also a significant decrease in anxiety symptoms among those taking the probiotic vs controls (p = 0.01).” 
“Live probiotic Bifidobacterium lactis bacteria inhibit the toxic effects induced by wheat gliadin in epithelial cell culture” [2008 (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2453197/)%5D
From Intestinal Microbiota and Probiotics in Celiac Disease, 2014 (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135898/)
“Bifidobacterium infantis 35624 alleviates symptoms in IBS; this symptomatic response was associated with normalization of the ratio of an anti-inflammatory to a pro-inflammatory cytokine, suggesting an immune-modulating role for this organism, in this disorder.”[2005 (http://www.ncbi.nlm.nih.gov/pubmed/15765388)%5D
“a probiotic dietary supplement, containing four strains of lactic acid bacteria, on symptoms of IBS.. the probiotic combination was not significantly superior to the placebo in relieving symptoms of IBS” [2008 ] Note: Bifido works, Lacto does NOT.
“Bifidobacterium strains are generally regarded as less pro-inflammatory than Lactobacillus,” [2008 (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2640389/)%5D
“There were statistically significant difference in expansion of bacteria between the wholemeal and white flour (wholemeal more bifidobacteria, white more lactobacillus) (p = 0.02; p = 0.04, respectively).”[2014 (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065312/)%5D – so avoid food using white flour
“It has been demonstrated that levels of bifidobacteria and lactobacilli are reduced in CD patients, and thus, these bacteria have been seen as promising targets for probiotic therapy. However, there is still a lack of consensus regarding the shifts in bacterial composition, primarily at the species level. Thus, future studies should emphasize microbiota characterization with potential benefits to gut health. Strains capable of producing enzymes that degrade gliadin peptides and induce anti- inflammatory effects are believed to be better suited for the treatment of this disorder.” Intestinal Microbiota and Probiotics in Celiac Disease, 2014
My next post will look at commercial probiotics that are mainly bifidobacteria.